6-氟-3-羟基喹啉 | 1167056-03-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氟-3-羟基喹啉
• 英文名称: 6-Fluoroquinolin-3-ol
• CAS: 1167056-03-2
• 化学式: C₉H₆FNO
• mdl: MFCD12405089
• 分子量: 163.15
• InChiKey: FUEXQMHPXCXPMM-UHFFFAOYSA-N

物化性质

• 沸点：
  316.6±22.0 °C(Predicted)
• 密度：
  1.366±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319

文献信息

• [EN] PYRAZOLES AS MODULATORS OF HEMOGLOBIN<br/>[FR] PYRAZOLES UTILISÉS UTILISÉS COMME MODULATEURS DE L'HÉMOGLOBINE
  申请人：PFIZER

  公开号：WO2020109994A1

  公开（公告）日：2020-06-04

  The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

  这项发明涉及吡唑衍生物，其在医学上的应用，含有它们的组合物，其制备方法以及用于这些方法的中间体。更具体地，该发明涉及式(I)的HbS调节剂或其互变异构体，或者该调节剂或其互变异构体的药学上可接受的盐，其中X、Y、R2和R3如描述中所定义。HbS调节剂在治疗包括镰状细胞病（SCD）在内的广泛疾病中可能是有用的。
• Chemical compounds
  申请人：Pfizer Inc.

  公开号：US11014908B2

  公开（公告）日：2021-05-25

  The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

  本发明涉及吡唑衍生物、吡唑衍生物在医药中的用途、含有吡唑衍生物的组合物、吡唑衍生物的制备工艺以及用于此类工艺的中间体。 本发明尤其涉及式 (I) 的 HbS 调节剂 或其同系物，或所述调节剂或其同系物的药学上可接受的盐，其中 X、Y、R2 和 R3 如描述中所定义。 HbS 调节剂可用于治疗多种疾病，包括镰状细胞病（SCD）。
• PYRAZOLES AS MODULATORS OF HEMOGLOBIN
  申请人：Pfizer Inc.

  公开号：EP3886984A1

  公开（公告）日：2021-10-06
• Chemical Compounds
  申请人：Pfizer Inc.

  公开号：US20200172512A1

  公开（公告）日：2020-06-04

  The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R 2 and R 3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).